20 August 2026, 04:34 PM
Medical device software no longer stays the same after launch. AI models improve, new clinical data becomes available, and performance can change over time. For manufacturers, the real challenge is not just building an effective AI-enabled device, but deciding how future updates will fit into FDA regulatory compliance without creating unnecessary regulatory hurdles.
One detail is worth clearing up from the beginning. An FDA PCCP (Predetermined Change Control Plan) is not something every AI medical device needs. It is an optional approach that manufacturers can use in specific situations. FDA published the final guidance on December 3, 2024, and the current guidance document is dated August 18, 2025, so older draft guidance should not be treated as the current framework.
If you are preparing an AI device submission, understanding when a PCCP makes sense is only the starting point. The bigger question is what the FDA expects you to document so future changes remain predictable, justified, and easier to manage. That is exactly what this guide covers.
Authorized under Section 3308 of the Food and Drug Omnibus Reform Act (FDORA) / Section 515C of the FD&C Act, an FDA PCCP establishes explicit prospective boundaries for post-market software changes.
An FDA PCCP (Predetermined Change Control Plan) is a document submitted as part of a medical device marketing application, including an FDA 510(k) submission. It describes specific future modifications a manufacturer plans to make and the procedures that will be used to develop, validate, implement, and evaluate those changes. FDA reviews and authorizes the PCCP as part of the marketing submission process.
Its main advantage is regulatory efficiency. If a future modification falls within the FDA-authorized PCCP and follows the approved procedures, it can be implemented without another premarket submission. This does not give manufacturers unlimited freedom to modify an AI model. Changes outside the authorized scope still require FDA evaluation.
A manufacturer also cannot prepare an internal document, call it a PCCP, and use it to bypass future submissions. The plan has regulatory value only after FDA review and establishment of the appropriate marketing authorization.
Source: https://qualysec.com/fda-pccp-guidance/
One detail is worth clearing up from the beginning. An FDA PCCP (Predetermined Change Control Plan) is not something every AI medical device needs. It is an optional approach that manufacturers can use in specific situations. FDA published the final guidance on December 3, 2024, and the current guidance document is dated August 18, 2025, so older draft guidance should not be treated as the current framework.
If you are preparing an AI device submission, understanding when a PCCP makes sense is only the starting point. The bigger question is what the FDA expects you to document so future changes remain predictable, justified, and easier to manage. That is exactly what this guide covers.
Authorized under Section 3308 of the Food and Drug Omnibus Reform Act (FDORA) / Section 515C of the FD&C Act, an FDA PCCP establishes explicit prospective boundaries for post-market software changes.
An FDA PCCP (Predetermined Change Control Plan) is a document submitted as part of a medical device marketing application, including an FDA 510(k) submission. It describes specific future modifications a manufacturer plans to make and the procedures that will be used to develop, validate, implement, and evaluate those changes. FDA reviews and authorizes the PCCP as part of the marketing submission process.
Its main advantage is regulatory efficiency. If a future modification falls within the FDA-authorized PCCP and follows the approved procedures, it can be implemented without another premarket submission. This does not give manufacturers unlimited freedom to modify an AI model. Changes outside the authorized scope still require FDA evaluation.
A manufacturer also cannot prepare an internal document, call it a PCCP, and use it to bypass future submissions. The plan has regulatory value only after FDA review and establishment of the appropriate marketing authorization.
Source: https://qualysec.com/fda-pccp-guidance/